Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α

Authors: Caroline MM Gits, Patricia F van Kuijk, Jonneke CWM de Rijck, Nikky Muskens, Moniek BE Jonkers, Wilfred F van IJcken, Ron HJ Mathijssen, Jaap Verweij, Stefan Sleijfer, Erik AC Wiemer

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Hypoxia is often encountered in solid tumors and known to contribute to aggressive tumor behavior, radiation- and chemotherapy resistance resulting in a poor prognosis for the cancer patient. MicroRNAs (miRNAs) play a role in the regulation of the tumor cell response to hypoxia, however, not much is known about the involvement of miRNAs in hypoxic signalling pathways in soft tissue sarcomas (STS).

Method

A panel of twelve STS cell lines was exposed to atmospheric oxygen concentrations (normoxia) or 1% oxygen (hypoxia) for up to 48 h. Hypoxic conditions were verified and miRNA expression profiles were assessed by LNA™ oligonucleotide microarrays and RT-PCR after 24 h. The expression of target genes regulated by hypoxia responsive miRNAs is examined by end-point PCR and validated by luciferase reporter constructs.

Results

Exposure of STS cell lines to hypoxic conditions gave rise to upregulation of Hypoxia Inducible Factor (HIF) 1α protein levels and increased mRNA expression of HIF1 target genes CA9 and VEGFA. Deregulation of miRNA expression after 24 h of hypoxia was observed. The most differentially expressed miRNAs (p < 0.001) in response to hypoxia were miR-185-3p, miR-485-5p, miR-216a-5p (upregulated) and miR-625-5p (downregulated). The well-known hypoxia responsive miR-210-3p could not be reliably detected by the microarray platform most likely for technical reasons, however, its upregulation upon hypoxic stress was apparent by qPCR. Target prediction algorithms identified 11 potential binding sites for miR-485-5p and a single putative miR-210-3p binding site in the 3’UTR of HIF3α, the least studied member of the HIF family. We showed that HIF3α transcripts, expressing a 3’UTR containing the miR-485-5p and miR-210-3p target sites, are expressed in all sarcoma cell lines and upregulated upon hypoxia. Additionally, luciferase reporter constructs containing the 3’UTR of HIF3α were used to demonstrate regulation of HIF3α by miR-210-3p and miR-485-5p.

Conclusion

Here we provide evidence for the miRNA mediated regulation of HIF3α by hypoxia responsive miRNAs in STS, which may help to tightly regulate and fine-tune the hypoxic response. This provides a better insight into the mechanisms underlying the hypoxic response in STS and may ultimately yield information on novel prognostic and predictive markers or targets for treatment.
Appendix
Available only for authorised users
Literature
1.
Harris AL: Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2 (1): 38-47. 10.1038/nrc704.CrossRefPubMed
2.
Wang GL, Semenza GL: General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993, 90 (9): 4304-4308. 10.1073/pnas.90.9.4304.CrossRefPubMedPubMedCentral
3.
Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y: A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A. 1997, 94 (9): 4273-4278. 10.1073/pnas.94.9.4273.CrossRefPubMedPubMedCentral
4.
Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC: Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003, 23 (24): 9361-9374. 10.1128/MCB.23.24.9361-9374.2003.CrossRefPubMedPubMedCentral
5.
Heikkila M, Pasanen A, Kivirikko KI, Myllyharju J: Roles of the human hypoxia-inducible factor (HIF)-3alpha variants in the hypoxia response. Cell Mol Life Sci. 2011, 68 (23): 3885-3901. 10.1007/s00018-011-0679-5.CrossRefPubMed
6.
Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M: Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem. 2003, 278 (13): 11032-11040. 10.1074/jbc.M208681200.CrossRefPubMed
7.
Pasanen A, Heikkila M, Rautavuoma K, Hirsila M, Kivirikko KI, Myllyharju J: Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2. Int J Biochem Cell Biol. 2010, 42 (7): 1189-1200. 10.1016/j.biocel.2010.04.008.CrossRefPubMed
8.
Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N: Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun. 2001, 287 (4): 808-813. 10.1006/bbrc.2001.5659.CrossRefPubMed
9.
Maynard MA, Evans AJ, Hosomi T, Hara S, Jewett MA, Ohh M: Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J. 2005, 19 (11): 1396-1406. 10.1096/fj.05-3788com.CrossRefPubMed
10.
Maynard MA, Evans AJ, Shi W, Kim WY, Liu FF, Ohh M: Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle. 2007, 6 (22): 2810-2816. 10.4161/cc.6.22.4947.CrossRefPubMed
11.
Tanaka T, Wiesener M, Bernhardt W, Eckardt KU, Warnecke C: The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction. Biochem J. 2009, 424 (1): 143-151. 10.1042/BJ20090120.CrossRefPubMed
12.
Airley RE, Phillips RM, Evans AE, Double J, Burger AM, Feibig HH, West CM, Stratford IJ: Hypoxia-regulated glucose transporter glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (first translational award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int J Oncol. 2005, 26 (6): 1477-1484.PubMed
13.
Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56 (19): 4509-4515.PubMed
14.
Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996, 56 (5): 941-943.PubMed
15.
Nordsmark M, Hoyer M, Keller J, Nielsen OS, Jensen OM, Overgaard J: The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1996, 35 (4): 701-708. 10.1016/0360-3016(96)00132-0.CrossRefPubMed
16.
Wiemer EA: The role of microRNAs in cancer: no small matter. Eur J Cancer. 2007, 43 (10): 1529-1544. 10.1016/j.ejca.2007.04.002.CrossRefPubMed
17.
Chen CZ: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005, 353 (17): 1768-1771. 10.1056/NEJMp058190.CrossRefPubMed
18.
19.
20.
Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007, 302 (1): 1-12. 10.1016/j.ydbio.2006.08.028.CrossRefPubMed
21.
Li X, Wu Z, Fu X, Han W: A microRNA component of the neoplastic microenvironment: microregulators with far-reaching impact. Biomed Res Int. 2013, 2013: 762183-PubMed
22.
23.
Crosby ME, Devlin CM, Glazer PM, Calin GA, Ivan M: Emerging roles of microRNAs in the molecular responses to hypoxia. Curr Pharm Des. 2009, 15 (33): 3861-3866. 10.2174/138161209789649367.CrossRefPubMed
24.
Kulshreshtha R, Davuluri RV, Calin GA, Ivan M: A microRNA component of the hypoxic response. Cell Death Differ. 2008, 15 (4): 667-671. 10.1038/sj.cdd.4402310.CrossRefPubMed
25.
Kulshreshtha R, Ferracin M, Negrini M, Calin GA, Davuluri RV, Ivan M: Regulation of microRNA expression: the hypoxic component. Cell Cycle. 2007, 6 (12): 1426-1431.CrossRefPubMed
26.
Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M: A microRNA signature of hypoxia. Mol Cell Biol. 2007, 27 (5): 1859-1867. 10.1128/MCB.01395-06.CrossRefPubMedPubMedCentral
27.
Cha ST, Chen PS, Johansson G, Chu CY, Wang MY, Jeng YM, Yu SL, Chen JS, Chang KJ, Jee SH, Tan C, Lin MT, Kuo ML: MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res. 2010, 70 (7): 2675-2685. 10.1158/0008-5472.CAN-09-2448.CrossRefPubMed
28.
Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Chandrashekhar YS, Hall JL, Roy S, Zeng Y, Ramakrishnan S: Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. J Clin Invest. 2010, 120 (11): 4141-4154. 10.1172/JCI42980.CrossRefPubMedPubMedCentral
29.
Kelly TJ, Souza AL, Clish CB, Puigserver P: A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol. 2011, 31 (13): 2696-2706. 10.1128/MCB.01242-10.CrossRefPubMedPubMedCentral
30.
Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, Goto H, Takahashi T: Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res. 2008, 68 (14): 5540-5545. 10.1158/0008-5472.CAN-07-6460.CrossRefPubMed
31.
Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L, Jiang BH: MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2012, 40 (2): 761-774. 10.1093/nar/gkr730.CrossRefPubMed
32.
Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D, Lowenstein CJ: P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A. 2010, 107 (14): 6334-6339. 10.1073/pnas.0911082107.CrossRefPubMedPubMedCentral
33.
Pothof J, Verkaik NS, van IJcken W, Wiemer EA, TA VT, van der Horst GT, Jaspers NG, van Gent DC, Hoeijmakers JH, Persengiev SP: MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J. 2009, 28 (14): 2090-2099. 10.1038/emboj.2009.156.CrossRefPubMedPubMedCentral
34.
Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3 (6): 1101-1108. 10.1038/nprot.2008.73.CrossRefPubMed
35.
Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P, Harris AL: Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 2001, 61 (13): 5262-5267.PubMed
36.
Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60 (24): 7075-7083.PubMed
37.
Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003, 9 (6): 677-684. 10.1038/nm0603-677.CrossRefPubMed
38.
Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005, 120 (1): 15-20. 10.1016/j.cell.2004.12.035.CrossRefPubMed
39.
Greither T, Wurl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschlager C, Holzhausen HJ, Wach S, Eckert AW, et al: Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer. 2012, 130 (5): 1230-1235. 10.1002/ijc.26109.CrossRefPubMed
40.
Crosby ME, Kulshreshtha R, Ivan M, Glazer PM: MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 2009, 69 (3): 1221-1229. 10.1158/0008-5472.CAN-08-2516.CrossRefPubMedPubMedCentral
41.
Guimbellot JS, Erickson SW, Mehta T, Wen H, Page GP, Sorscher EJ, Hong JS: Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Med Genomics. 2009, 2: 15-10.1186/1755-8794-2-15.CrossRefPubMedPubMedCentral
42.
Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ: High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer. 2007, 6: 5-10.1186/1476-4598-6-5.CrossRefPubMedPubMedCentral
43.
Xu X, Jia R, Zhou Y, Song X, Wang J, Qian G, Ge S, Fan X: Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol. 2011, 38 (5): 1385-1393.PubMed
44.
45.
46.
Bruning U, Cerone L, Neufeld Z, Fitzpatrick SF, Cheong A, Scholz CC, Simpson DA, Leonard MO, Tambuwala MM, Cummins EP, Taylor CT: MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol Cell Biol. 2011, 31 (19): 4087-4096. 10.1128/MCB.01276-10.CrossRefPubMedPubMedCentral
47.
Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ: Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009, 35 (6): 856-867. 10.1016/j.molcel.2009.09.006.CrossRefPubMedPubMedCentral
48.
Chen KF, Lai YY, Sun HS, Tsai SJ: Transcriptional repression of human cad gene by hypoxia inducible factor-1alpha. Nucleic Acids Res. 2005, 33 (16): 5190-5198. 10.1093/nar/gki839.CrossRefPubMedPubMedCentral
49.
Haque I, Banerjee S, Mehta S, De A, Majumder M, Mayo MS, Kambhampati S, Campbell DR, Banerjee SK: Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1alpha-TWIST signaling networks in human breast cancer cells. J Biol Chem. 2011, 286 (50): 43475-43485. 10.1074/jbc.M111.284158.CrossRefPubMedPubMedCentral
50.
Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F, Maroulakou I, Struhl K, Tsichlis PN: Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res. 2011, 71 (13): 4720-4731. 10.1158/0008-5472.CAN-11-0365.CrossRefPubMedPubMedCentral
51.
Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH, Hsu JL, Wu Y, Lam YC, James BP, Liu X, Liu CG, Patel DJ, Hung MC: EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature. 2013, 497 (7449): 383-387. 10.1038/nature12080.CrossRefPubMedPubMedCentral
52.
Donker RB, Mouillet JF, Nelson DM, Sadovsky Y: The expression of Argonaute2 and related microRNA biogenesis proteins in normal and hypoxic trophoblasts. Mol Hum Reprod. 2007, 13 (4): 273-279. 10.1093/molehr/gam006.CrossRefPubMed
53.
Augstein A, Poitz DM, Braun-Dullaeus RC, Strasser RH, Schmeisser A: Cell-specific and hypoxia-dependent regulation of human HIF-3alpha: inhibition of the expression of HIF target genes in vascular cells. Cell Mol Life Sci. 2011, 68 (15): 2627-2642. 10.1007/s00018-010-0575-4.CrossRefPubMed
54.
Makino Y, Uenishi R, Okamoto K, Isoe T, Hosono O, Tanaka H, Kanopka A, Poellinger L, Haneda M, Morimoto C: Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): a negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells. J Biol Chem. 2007, 282 (19): 14073-14082. 10.1074/jbc.M700732200.CrossRefPubMed
55.
56.
Devlin C, Greco S, Martelli F, Ivan M: miR-210: more than a silent player in hypoxia. IUBMB Life. 2011, 63 (2): 94-100.PubMedPubMedCentral
57.
Ivan M, Harris AL, Martelli F, Kulshreshtha R: Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med. 2008, 12 (5A): 1426-1431. 10.1111/j.1582-4934.2008.00398.x.CrossRefPubMedPubMedCentral
58.
Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, Rajaram V, Bonaldo Mde F, Wang D, Goldman S, Tomita T, Soares MB: Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One. 2011, 6 (10): e25114-10.1371/journal.pone.0025114.CrossRefPubMedPubMedCentral
59.
Cohen JE, Lee PR, Chen S, Li W, Fields RD: MicroRNA regulation of homeostatic synaptic plasticity. Proc Natl Acad Sci U S A. 2011, 108 (28): 11650-11655. 10.1073/pnas.1017576108.CrossRefPubMedPubMedCentral
60.
Faghihi MA, Zhang M, Huang J, Modarresi F, Van der Brug MP, Nalls MA, Cookson MR, St-Laurent G, Wahlestedt C: Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol. 2010, 11 (5): R56-10.1186/gb-2010-11-5-r56.CrossRefPubMedPubMedCentral
61.
Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, An HJ: Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology. 2010, 57 (5): 734-743. 10.1111/j.1365-2559.2010.03686.x.CrossRefPubMed
Metadata
Title
MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α
Authors
Caroline MM Gits
Patricia F van Kuijk
Jonneke CWM de Rijck
Nikky Muskens
Moniek BE Jonkers
Wilfred F van IJcken
Ron HJ Mathijssen
Jaap Verweij
Stefan Sleijfer
Erik AC Wiemer
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-429

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Study protocol

Study protocol: a randomised controlled trial of a theory-based online intervention to improve sun safety among Australian adults

Research article

MicroRNA-27a promotes proliferation and suppresses apoptosis by targeting PLK2in laryngeal carcinoma

Research article

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells

Research article

Outcome after intensity modulated radiotherapy for anaplastic thyroid carcinoma

Research article

Second primary cancer risk - the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study

Research article

Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits